Maxigesic IV(R) licensed in six new European nations

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com





Market and media release 30 July 2020

Maxigesic IV
®
licensed in six new European nations
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) has signed an exclusive Maxigesic IV
®

licensing and supply agreement for Bulgaria, Cyprus, the Czech Republic, Hungary,
Romania and Slovakia, countries with a combined population of more than 53
million*.
The agreement is with the Cyprus based multinational pharmaceutical company,
Medochemie, which earlier this year signed a licensing agreement for Maxigesic IV®
for Ukraine and the nine countries of the Commonwealth of Independent States.
AFT Pharmaceutical’s Managing Director Dr Hartley Atkinson says: “We are delighted
to further strengthen our partnership with Medochemie. It is a strong, dynamic partner
in this region and its business teams have an excellent understanding of their local
markets.”
Maxigesic IV
®
regulatory approvals in the six European countries covered by this
agreement are expected to conclude in the next few months, with sales then
expected in the 2021calendar year.
Maxigesic IV
®
(Paracetamol 1000mg+ Ibuprofen 300mg solution for infusion) is an
intravenous formulation developed as a line extension to Maxigesic tablets, for use
post-operatively in hospitals when patients cannot take a medicine orally.
A major Phase 3 clinical trial conducted in the USA found that Maxigesic IV provided
significantly better pain relief than either paracetamol (acetaminophen) IV or
ibuprofen IV alone in the same doses.**
Following on from the registration of Maxigesic IV
®
in Australia and New Zealand in
mid-2019, AFT has now licensed the medication in more than 90 countries. Meanwhile,
the tablet form of Maxigesic has been licensed in more than 125 countries.
For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com



About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical business with a broad range of
products, both developed itself and in-licensed from third parties. AFT’s products
cover all major pharmaceutical distribution channels: over-the-counter, prescription
and hospital. Historically, AFT’s home markets have been Australia, New Zealand and
South-East Asia. However, the company is out-licensing its own products to licensees
and distributors to sell in an increasing number of countries around the world. The
company’s intensive Research and Development programme forms the basis of its
international sales strategy. For more information about the company, visit our website
www.aftpharm.com
.
About Medochemie
Medochemie Ltd is a multinational pharmaceutical and consumer healthcare
company headquartered in Limassol, Cyprus. Medochemie develops, licenses,
manufactures, markets, and distributes branded generic and OTC products as well as
their own brands in more than 107 countries.

References
* 2019 population. Source: Statista, 2020
**Daniels, S.E, Playne, R., Stanescu, I., Zhang, J., Gottlieb, I.J, Atkinson, H.C. (2019).
Efficacy and safety of an intravenous acetaminophen/ibuprofen fixed-dose
combination after bunionectomy: A randomized, double-blind, factorial, placebo-
controlled trial. Clinical Therapeutics 41 (10): 1982-1995. Research sponsored by AFT
Pharmaceuticals.